Bucillamine
Phase 3Small molecule
Bucillamine is one of 59 small molecule programs targeting Cystinuria. It is currently in Phase 3.
3
Indications
5
Total Trials
0
Active Trials
58
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Bucillamine
RRevive Therapeutics, Ltd.
Phase 3
Aldactone
PfizerPreclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Piperacillin/tazobactam
PfizerPreclinical
Olokizumab
UCBPreclinical
Vit D
PPost Graduate Institute of Medical Education and Research, Chandigarh
Preclinical
DAS181
AAnsun Biopharma, Inc.
Preclinical
Exoflo
DDirect Biologics, LLC
Preclinical
Tpa
UUniversity of Florida
Preclinical
Opaganib
RRedHill Biopharma Limited
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Treatment1 trial
Rheumatoid Arthritis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bucillamine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- RRevive Therapeutics, Ltd.